Focus: Satellos Bioscience is a public biotech company focused on stimulating the body's innate tissue repair and regeneration mechanisms using biologic and small molecule drugs, with a specialized focus on rare diseases. The company operates as a publicly-traded entity on the MSLE ticker with headquarters in Toronto, Ontario.
Profile data last refreshed 16h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Satellos Bioscience to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Satellos Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Satellos Bioscience's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Why Satellos Bioscience (MSLE) could be the anchor your portfolio needs (Smart Money Flows) 2026-05-08 - Mean Reversion Trade - The Legal Advocate
Why Satellos Bioscience (MSLE) could be the anchor your portfolio needs (Smart Money Flows) 2026-05-08 - Mean Reversion Trade The Legal Advocate
Why Satellos Bioscience (MSLE) could be the anchor your portfolio needs (Smart Money Flows) 2026-05-08 - Bearish Pattern Stocks - The Legal Advocate
Why Satellos Bioscience (MSLE) could be the anchor your portfolio needs (Smart Money Flows) 2026-05-08 - Bearish Pattern Stocks The Legal Advocate
Discover the Top 4 Canadian Pharma Stocks of 2025 - Investing News Network
Discover the Top 4 Canadian Pharma Stocks of 2025 Investing News Network
Satellos Bioscience (MSLE) funds 2027 runway while advancing Phase 2 DMD trials - Stock Titan
Satellos Bioscience (MSLE) funds 2027 runway while advancing Phase 2 DMD trials Stock Titan
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference - Investing News Network
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference Investing News Network
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company